Novartis Gets Positive Result From Breast-Cancer Drug Trial
27 Março 2023 - 2:56AM
Dow Jones News
By Cecilia Butini
Novartis AG said Monday that a trial evaluating breast-cancer
drug Kisqali met its primary endpoint during an interim
analysis.
The drug is shown to significantly reduce the risk of disease
recurrence when used together with an endocrine therapy in patients
with certain types of early breast cancers at risk of recurrence,
the company said.
The Phase 3 trial, named Natalee, was stopped early as the
primary endpoint has been met, Novartis said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 27, 2023 01:41 ET (05:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
